Format

Send to

Choose Destination
Semin Hematol. 2008 Apr;45(2):90-4. doi: 10.1053/j.seminhematol.2008.02.003.

Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma.

Author information

1
Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA. bsk@medicine.wisc.edu

Abstract

Although the use of monoclonal antibodies as single agents has had a tremendous impact on the care of patients with non-Hodgkin's lymphoma (NHL), the greatest benefit has been generated by the addition of monoclonal antibodies to conventional cytotoxic chemotherapy. Rituximab is the monoclonal antibody responsible for all clinical improvement noted to date. The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP regimen) improves the response rate, progression-free survival (PFS), and overall survival (OS) in diffuse large B-cell lymphoma (DLBCL). Adding rituximab to CHOP chemotherapy improves response rates and PFS in mantle cell lymphoma (MCL). Finally, the addition of rituximab to a variety of chemotherapy regimens improves the response rates, PFS, and OS in follicular lymphoma (FL). Several other (epratuzumab, bevacizumab, alemtuzumab) monoclonal antibody-chemotherapy combinations are currently under study in NHL. This review will summarize the data supporting the addition of rituximab to chemotherapy in NHL and discuss preliminary data regarding the use of other monoclonal antibodies in combination with chemotherapy.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center